Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Survival Outcomes of Liver Metastasectomy in Colorectal Cancer Cases: A Single-Center Analysis in Turkey

  • Cokmert, Suna (Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University) ;
  • Ellidokuz, Hulya (Department of Preventive Oncology, Insitute of Oncology, School of Medicine, Dokuz Eylul University) ;
  • Demir, Lutfiye (Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University) ;
  • Fuzun, Mehmet (Department of Surgery, School of Medicine, Dokuz Eylul University) ;
  • Astarcioglu, Ibrahim (Department of Surgery, School of Medicine, Dokuz Eylul University) ;
  • Aslan, Deniz (Department of Medical Oncology, School of Medicine, Dokuz Eylul University) ;
  • Yilmaz, Ugur (Department of Medical Oncology, Medical Park Hospital, Izmir University) ;
  • Oztop, Ilhan (Department of Medical Oncology, School of Medicine, Dokuz Eylul University)
  • Published : 2014.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The purpose of this study was to analyze our series of liver resections for metastatic colorectal carcinoma (mCRC) to determine prognostic factors affecting survival and to evaluate the potential roles of neoadjuvant or adjuvant chemotherapy. Materials and Methods: Ninety-nine patients who underwent metastasectomy for liver metastases due to colorectal cancer at the Department of Medical Oncology, 9 Eylul University Hospital between 1996 and 2010 were evaluated in this study. The patients were followed through July 2013. Demographic, perioperative, laboratory, radiological and chemotherapy as well as survival data were obtained by retrospective chart review. Results: In 47 (47.5%) patients, liver metastases were unresectable at initial evaluation; the remaining 52 (52.5%) patients exhibited resectable liver metastases. Simultaneous hepatic resection was applied to 52 (35.4%) patients with synchronous metastasis, whereas 5 (64.5%) patients underwent hepatic resection after neoadjuvant chemotherapy. Forty-two patients with metachronous metastasis underwent hepatic resection following neoadjuvant chemotherapy. R0 resection was obtained in 79 (79.8%) patients. A second hepatectomy was performed in 22 (23.2%) patients. Adjuvant chemotherapy was given to 85 (85.9%) patients after metastasectomy. The median disease-free and overall survivals after initial metastasectomy were 12 and 37 months, respectively, the 1-year, 3-year and 5-year disease-free survival (DFS) and overall survival (OS) rates being 46.5%, 24.3% and 17.9%and 92.3%, 59.0% and 39.0%, respectively. On multivariate analysis, the primary tumor site, tumor differentiation, resection margin and DFS were independent factors predicting better overall survival. Conclusions: In selected cases, hepatic metastasectomy for mCRC to the liver can result in long-term survival. Neoadjuvant chemotherapy did not exert a positive effect on DFS or OS. Adjuvant chemotherapy also did not appear to impact DFS and OS.

Keywords

References

  1. Castaing D, Vibert E, Ricca L, et al (2009). Oncologic results of laparoscopic versus open hepatectomy in two specialized centers. Ann Surg, 250, 849-55. https://doi.org/10.1097/SLA.0b013e3181bcaf63
  2. Chua TC, Liauw W, Koong HN, et al (2011). Surgical therapies in metastatic colorectal cancer with a potential for cure. Am J Clin Oncol, 34, 326-31. https://doi.org/10.1097/COC.0b013e3181dbb9ad
  3. Couinaud C (1954). Anatomic principles of left and right regulated hepatectomy: technics. J Chir (Paris), 70, 933-66.
  4. Cui YL, Li HK, Zhou HY, et al (2013). Correlations of tumor-associated macrophage subtypes with liver metastases of colorectal cancer. Asian Pac J Cancer Prev, 14, 1003-7. https://doi.org/10.7314/APJCP.2013.14.2.1003
  5. Dong H, Tang J, Li LH, et al (2013). Serum carbohydrate antigen 19-9 as an indicator of liver metastasis in colorectal carcinoma cases. Asian Pac J Cancer Prev, 14, 909-13. https://doi.org/10.7314/APJCP.2013.14.2.909
  6. Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  7. Fong Y, Fortner J, Sun RL, et al (1999). Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg, 230, 309-18. https://doi.org/10.1097/00000658-199909000-00004
  8. Gallinger S, Biagi JJ, Fletcher GG, et al (2013). Liver resection for colorectal cancer metastases. Curr Oncol, 20, 255-65. https://doi.org/10.3747/co.20.1341
  9. Giacchetti S, Itzhaki M, Gruia G, et al (1999). Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol, 10, 663-9. https://doi.org/10.1023/A:1008347829017
  10. Hsu Y-N, Lin J-K, Chen W-S, et al (2011). A new classification scheme for recurrent or metastatic colon cancer after liver metastasectomy. J Chinese Med Assoc, 74, 493-9. https://doi.org/10.1016/j.jcma.2011.09.004
  11. Ike H, Shimada H, Togo S, et al (2002). Sequential resection of lung metastases following partial hepatectomy for colorectal cancer. Br J Surg, 89, 1164-8. https://doi.org/10.1046/j.1365-2168.2002.02174.x
  12. Jain S, Sacchi M, Vrachnos P, et al (2005). Recent advances in the treatment of colorectal liver metastases. Hepatogastroenterology, 52, 1567-84.
  13. Jones RP, Jackson R, Dunne DFJ, et al (2012). Systematic review and metaanalysis of follow-up after hepatectomy for colorectal liver metastases. Br J Surg, 99, 477-86. https://doi.org/10.1002/bjs.8667
  14. Jones RP, Malik HZ, Fenwick SW, et al (2013) Perioperative chemotherapy for resectable colorectal liver metastases: where now? Eur J Surg Oncol, 39, 807-11. https://doi.org/10.1016/j.ejso.2013.04.002
  15. Kato T, Yasui K, Hirai T, et al (2003). Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum, 46, 22-31.
  16. Lopez-Gomez M, Cejas P, Merino M, et al (2012) Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment? Clin Transl Oncol, 14, 641-58. https://doi.org/10.1007/s12094-012-0853-8
  17. Morise Z, Sugioka A, Fujita J, et al (2006). Does repeated surgery improve the prognosis of colorectal liver metastases? J Gastrointest Surg, 10, 6-11. https://doi.org/10.1016/j.gassur.2005.09.006
  18. Mitry E, Fields ALA, Bleiberg H, et al (2008). Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol, 26, 4906-11. https://doi.org/10.1200/JCO.2008.17.3781
  19. Nikfarjam M, Shereef S, Kimchi ET, et al (2009). Survival outcomes of patients with colorectal liver metastases following hepatic resection or ablation in the era of effective chemotherapy. Ann Surg Oncol, 16, 1860-7. https://doi.org/10.1245/s10434-008-0225-3
  20. Nordlinger B, Sorbye H, Debois M, et al (2005). Feasibility and risks of preoperative chemotherapy with FOLFOX 4 and surgery for resectable colorectal liver metastases: Interim results of the EORTC Intergroup randomized phase III study 40983. J Clin Oncol, 23, 253.
  21. Pawlik TM, Choti MA (2007). Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg, 11, 1057-77. https://doi.org/10.1007/s11605-006-0061-3
  22. Portier G, Elias D, Bouche O, et al (2006). Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol, 24, 4976-82. https://doi.org/10.1200/JCO.2006.06.8353
  23. Rebecca Siegel, Carol De Santis, Katherine Virgo, et al (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin, 62, 220-41. https://doi.org/10.3322/caac.21149
  24. Reddy RH, Kumar B, Shah R, et al (2004). Staged pulmonary and hepatic metastasectomy in colorectal cancer is it worth it? Eur J Cardiothorac Surg, 25, 151-4. https://doi.org/10.1016/j.ejcts.2003.11.020
  25. Sato T, Konishi K, Yabushita K, et al (1998). The time interval between primary colorectal carcinoma resection to occurrence of liver metastases is the most important factor for hepatic resection. Analysis of total course following primary resection of colorectal cancer. Int Surg, 83, 340-42.
  26. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J (1994). Factors influencing the natural history of colorectal liver metastases. Lancet, 343, 1405-10. https://doi.org/10.1016/S0140-6736(94)92529-1
  27. Sobin LH, Gospodarowicz MK (2009). Wittekind Ch Eds. TNM classification of malignant tumors, 7th ed. wiley-blackwell, oxford. 310 pages.
  28. Van Cutsem E, Nordlinger B, Adam R, et al (2006). Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer, 42, 2212-21. https://doi.org/10.1016/j.ejca.2006.04.012

Cited by

  1. Whole Liver Palliative Radiotherapy for Patients with Massive Liver Metastases vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6381
  2. Factors Affecting Prognosis in Metastatic Colorectal Cancer Patients vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.3015